ACCESS Newswire

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment

Share

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.

2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development

Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.

Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.

Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.

2025 Roadmap: Advancing BNT23001 into Clinical Trials

Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.

Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.

Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.

Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.

BNT23001: Advancing Toward Clinical Validation for MS Treatment

BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:

Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.

Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.

Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.

By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.

With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt

Cautionary Statement Regarding "Forward-Looking" Information

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.

Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.

SOURCE: BioNxt Solutions Inc.



View the original press release on accesswire.com

BioNxt Solutions Inc.

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

KALEO Frontman JJ Julius Son and Entrepreneur Robert Wessman to Launch Unique Limited-Edition Wine Collection at WineParis6.2.2025 07:08:00 CET | Press release

An Icelandic Merger of Music and Winemaking SAINT-CERNIN-DE-LABARDE, DORDOGNE, FRANCE / ACCESS Newswire / February 6, 2025 / JJ Julius Son, acclaimed frontman for the internationally renowned blues-rock band KALEO, and entrepreneur Robert Wessman have joined forces, creating a limited-edition wine collection. This collaboration highlights their shared Icelandic heritage and promises to deliver an exquisite experience for wine enthusiasts and music lovers. The wines were created in the summer of 2024, by JJ and Robert, at the Maison Wessman winery in France, blending countless samples from barrels in the maison's cellar, under the supervision of oenologist Julien Viaud, of Michel Rolland and Associates. JJ and Robert will formally launch the collection on Feb. 10, 2025, at the global trade fair "WineParis." "We are excited to embark on this journey together," said Robert Wessman. "The goal is to create wines that not only delight the palate but also tell a story of friendship and collab

Powerverse and AffinityEV Partner to Transform the EV Ecosystem6.2.2025 02:00:00 CET | Press release

LONDON, GB / ACCESS Newswire / February 6, 2025 / Powerverse, a leading AI-powered software company and AffinityEV, a pioneering automotive & energy tech platform that transforms dealership connectivity, today announced a partnership to revolutionise the EV ecosystem enabling OEMs & dealers to seamlessly integrate EV sales with smart home energy solutions. This collaboration integrates Powerverse's next generation Energy Operating System (EOS) with AffinityEV's dealership connectivity, creating a seamless end-to-end customer experience while unlocking new revenue streams for dealerships & OEMs. "This partnership accelerates EV adoption & empowers consumers to make smarter choices as they join the electric future," said Richard Britton, CEO at Powerverse. "By combining our AI-powered energy management platform with AffinityEV's leading automotive solution, we're removing the barriers that hinder EV sales and enhancing dealership & customer experiences." This industry-first integration t

Blackbox Press Event and Regional Government Roundtable5.2.2025 22:00:00 CET | Press release

TOKYO, JP / ACCESS Newswire / February 5, 2025 / From 2 p.m. to 4 p.m. on Jan. 29, Blackbox held its first in-house media event. We were aiming to start off small, so we were pleasantly surprised with the turnout - thank you to all the press and ecosystem representatives who made the time to come by.BLACKBOX EVENT Roundtable With Regional Delegates It being our first event, we began by explaining Blackbox's mission statement and the social context that led to our launch. General Manager Taiki Iwasaki talked about the growing support for startups - especially foreign startups - in Japan over the last few years. We are now roughly midway through previous PM Kishida's five-year Startup Development plan, and the landscape is indeed changing. Currently over 700 Startup Visas have been issued, with well over half of them maturing to full-time Business Management Visas. And yet there remains the issue of Japan being a black box to outsiders, especially within the business sphere. Even informa

Polaris Renewable Energy Declares Quarterly Dividend5.2.2025 07:50:00 CET | Press release

TORONTO, ON / ACCESS Newswire / February 5, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on February 28th to shareholders of record at the close of business on February 17th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's o

Preservica and Oyster IMS Partner to Future-Proof Microsoft 365 Data with Active Digital Preservation5.2.2025 04:00:00 CET | Press release

OXFORD, UK / ACCESS Newswire / February 5, 2025 / Preservica, the leader in Active Digital Preservation™ archiving, has today announced a partnership with Oyster IMS, an expert consultancy-led business serving transnational agencies, global enterprises, local authorities and SMEs. Oyster IMS is now an authorized reseller of Preservica's Enterprise and Preserve365® technology and will support Microsoft 365 customers adopting a strong information governance framework for high-value, long-term content and those preparing for AI implementations. As digital content continues to grow in volume and complexity, having a robust and secure foundation of instantly useable, reliable and trusted long-term data has become a strategic imperative, essential for cutting compliance risk and leveraging AI. This is the arena in which Oyster IMS works with a set of clients ranging from SMEs to multinationals, and from local authorities to international governmental bodies. "I'm delighted to establish a for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye